Affibody is a Swedish biotechnology company developing next generation biologics based on the company’s unique proprietary technology platform
Regulatory
2024-12-10
Affibody’s Licensee ACELYRIN Announces Top-line Results for Izokibep in Uveitis
News
2024-10-20
event
13 Jan
PepTalk January 13-16, San Diego, USA
There are currently no posts in the reports and events archive.
Affibody’s broad pipeline utilizes the strengths of our proprietary technology platform and strategically focuses on indications and targets where our technology can offer a competitive advantage based on scientific understanding.
It is the competence and the engagement of all coworkers that make Affibody an inspiring and exciting place to work at. We know we reach much further in innovation, efficiency, and quality by having a work place where we as coworkers care for each other, are ambitious and know and value our own contribution to the end result.